The detection and staging of prostate cancer (PCa) dramatically improved over the last decade due to wide introduction into the clinical practice of prostate-specific membrane antigen (PSMA)-targeting agents based on Glu-urea-Lys binding moiety. This evidence concerns the gene FOLH1 and prostate cancer.